Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782416 | 0.96 | ALDH1A1 (0.44) | ALDH1A1MAOBMEN1LMNATHRB | |
| SCHEMBL5711323 | 0.82 | LMNA (0.57) | ALDH1A1MEN1LMNATHRBBLM | |
| SCHEMBL19154057 | 0.81 | MEN1 (0.46) | ALDH1A1MEN1LMNATHRBBLM | |
| SCHEMBL5805651 | 0.80 | RAB9A (0.50) | ALDH1A1MAOBMEN1KMT2ATDP1 | |
| SCHEMBL29398181 | 0.80 | RAB9A (0.50) | ALDH1A1MAOBMEN1KMT2ATDP1 | |
| SCHEMBL14650356 | 0.79 | TRIM24 (0.46) | ALDH1A1MAOBMEN1LMNATHRB | |
| SCHEMBL29700474 | 0.79 | TRIM24 (0.46) | ALDH1A1MAOBMEN1LMNATHRB | |
| SCHEMBL1129691 | 0.79 | XDH (0.51) | ALDH1A1MAOBMEN1LMNATHRB | |
| SCHEMBL29354816 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MEN1LMNAKMT2AERN1 | |
| SCHEMBL4919575 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MEN1LMNAKMT2AERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108264490-B | 1,3, 5-triazine derivative and preparation method and application thereof | 湖北尚赛光电材料有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-108264490-A | 1,3,5- pyrrolotriazine derivatives and its preparation method and application | 湖北尚赛光电材料有限公司 | 2018-07-10 | — | — | CN | disclosed |
| US-6627656-B2 | Antagonists of the pain and inflammatory effects of E-type prostaglandins administered alone or in combination with analgesics, antipyretics, NSAIDs, antitussives, decongestants etc | MERCK FROSST CANADA LTD. (CA) | 2003-09-30 | — | — | US | disclosed |
| EP-1278734-A2 | METHOD OF TREATMENT USING PHENYL AND BIARYL DERIVATIVES AS PROSTAGLANDIN E INHIBITORS AND COMPOUNDS USEFUL THEREFORE | Merck Frosst Canada & Co. (CA) | 2003-01-29 | — | — | EP | disclosed |
| US-20020082266-A1 | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore | MERCK FROSST CANADA LTD. (CA) | 2002-06-27 | — | — | US | disclosed |
| WO-2001081312-A2 | METHOD OF TREATMENT USING PHENYL AND BIARYL DERIVATIVES AS PROSTAGLANDIN E INHIBITORS AND COMPOUNDS USEFUL THEREFORE | MERCK FROSST CANADA & CO. (CA) | 2001-11-01 | — | — | WO | disclosed |
| US-4760127-A | Reacting dihalogen aromatics and alkali metal sulfide in presence of a monohalogen compound and a monomercapto compound | BAYER AG (DE) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082266-A1 | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore | PTGER1, PTGS1, PTGES | ALDH1A1 300/4885MAOB 231/4885MEN1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.